InvestorsObserver
×
News Home

Thermogenesis Holdings Inc Up 1.86% To $1.88 After Earnings Miss

Tuesday, May 16, 2023 11:11 AM | InvestorsObserver Analysts

Mentioned in this article

Thermogenesis Holdings Inc Up 1.86% To $1.88 After Earnings Miss

Tuesday, May 16, 2023 - Thermogenesis Holdings Inc (THMO) reported downside earnings and revenues today.

The consensus among analysts for Thermogenesis Holdings Inc was for an earnings per share (EPS) loss of $0.31 per share. The firm failed to meet those projections, reporting an EPS loss of $3.88 per share, a negative surprise of $3.57 (-1152%). Profits rose 46% year-over-year after reporting an EPS loss of $7.20 per share in its year-ago quarter. The positive growth rate signals that the Healthcare company is performing well amid recent economic conditions.

Consensus analyst estimates were at $2.8 million. The Healthcare company missed on those expectations for its first quarter with revenue of $2.6 million, a negative revenue surprise of $228 thousand (8%). The firm managed negative 3% growth year-over-year due to Thermogenesis Holdings Inc reporting quarterly revenue of $2.7 million in its year-ago quarter. Thermogenesis Holdings Inc achieved a higher earnings growth rate than revenue, signaling that the business has improved its profit margin.

The stock is up 1.86% to $1.88 after the report.

Thermogenesis Holdings Inc's profit margins took a hit as earnings fell at a faster pace than revenues.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Thermogenesis Holdings Inc a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 27. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

ThermoGenesis Holdings Inc. develops commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking point-of-care applications and automation for immuno-oncology including its semi-automated functionally-closed CAR-TXpress platform which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App